LILRA4/ILT-7/CD85g Protein, Human (HEK293, His)

The LILRA4/ILT-7/CD85g protein is a coreceptor that critically limits the innate immune response during viral infection through FCER1G signaling.It negatively regulates TLR7 and TLR9 signaling and reduces IFNA1, IFNA2, IFNA4, IFNB1, and TNF production in dendritic cells exposed to influenza virus or CpG dinucleotides.LILRA4/ILT-7/CD85g Protein, Human (HEK293, His) is the recombinant human-derived LILRA4/ILT-7/CD85g protein, expressed by HEK293 , with C-His labeled tag.

LILRA4/ILT-7/CD85g protein functions as a coreceptor, exerting a pivotal role in limiting innate immune responses during viral infections, with signaling occurring through FCER1G. It acts as a negative regulator of TLR7 and TLR9 signaling cascades, demonstrated by its ability to down-regulate the production of IFNA1, IFNA2, IFNA4, IFNB1, and TNF in plasmacytoid dendritic cells exposed to influenza virus or CpG dinucleotides. Additionally, LILRA4/ILT-7/CD85g negatively modulates interferon production in response to interaction with BST2 on HIV-1 infected cells. The protein activates a signaling cascade in conjunction with FCER1G, leading to the phosphorylation of Src family and Syk kinases and subsequent mobilization of intracellular Ca(2+). Notably, LILRA4/ILT-7/CD85g does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells. The interaction between LILRA4/ILT-7/CD85g and FCER1G stabilizes the expression of both proteins at the cell membrane, emphasizing its crucial regulatory role in the innate immune response to viral pathogens.

Measured by its binding ability in a functional ELISA. Immobilized Human LILRA4 at 1 μg/mL (100 μL/well) can bind biotinylated Human ANGPTL7. The ED₅₀ for this effect is 58.08 ng/mL.

• 
  Measured by its binding ability in a functional ELISA. Immobilized Human LILRA4 at 1 μg/mL (100 μL/well) can bind biotinylated Human ANGPTL7. The ED₅₀ for this effect is 58.08 ng/mL.

Human

HEK293

C-His

P59901-1 (E24-N446)

23547  [NCBI]

ENLLKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVSGVSRKPSLLTLQGPVVTPGENLTLQCGSDVGYIRYTLYKEGADGLPQRPGRQPQAGLSQANFTLSPVSRSYGGQYRCYGAHNVSSEWSAPSDPLDILIAGQISDRPSLSVQPGPTVTSGEKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKYQAEFPMSPVTSAHAGTYRCYGSRSSNPYLLSHPSEPLELVVSGATETLNPAQKKSDSKTAPHLQDYTVEN

Approximately 60-75 kDa due to the glycosylation

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.